Back to top
more

Fluidigm Corporation (FLDM)

(Delayed Data from NSDQ)

$11.89 USD

11.89
2,070,276

-1.80 (-13.15%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.89 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Fluidigm (FLDM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Fluidigm (FLDM) delivered earnings and revenue surprises of -225.00% and -11.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Fluidigm (FLDM) Q4 Earnings Expected to Decline

by Zacks Equity Research

Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Looking for a Growth Stock? Why It is Time to Focus on Fluidigm (FLDM)

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Fluidigm (FLDM).

Fluidigm (FLDM) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Fluidigm (FLDM) delivered earnings and revenue surprises of 150.00% and 19.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Fluidigm (FLDM) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark

by Zacks Equity Research

BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.

    Urmimala Biswas headshot

    Coronavirus Test Makers With Scope to Maximize Investor Benefits

    by Urmimala Biswas

    The surge in new coronavirus infections broadens the scope for antigen and antibody tests.

    Fluidigm (FLDM) Looks Good: Stock Adds 8.7% in Session

    by Zacks Equity Research

    Fluidigm (FLDM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

    Implied Volatility Surging for Fluidigm (FLDM) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Fluidigm (FLDM) stock based on the movements in the options market lately.

    Analysts Estimate Fluidigm (FLDM) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Is Fluidigm (FLDM) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (FLDM) Outperforming Other Medical Stocks This Year?

    Sanghamitra Saha headshot

    Snap Up These 5 Stocks With Rising P/E

    by Sanghamitra Saha

    Bet on these top--ranked stocks with rising P/E to realize outsized gains.

      Earnings Preview: Fluidigm (FLDM) Q4 Earnings Expected to Decline

      by Zacks Equity Research

      Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Fluidigm (FLDM) Reports Q3 Loss, Misses Revenue Estimates

      by Zacks Equity Research

      Fluidigm (FLDM) delivered earnings and revenue surprises of 0.00% and -8.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

      Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

      by Zacks Equity Research

      Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

      by Zacks Equity Research

      Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Fluidigm (FLDM) Reports Q1 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Fluidigm (FLDM) delivered earnings and revenue surprises of -40.00% and 4.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

      Masimo Gets CE Mark for ANI Module, Enhances Root Platform

      by Zacks Equity Research

      Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.

      Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?

      by Zacks Equity Research

      Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.

      Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

      by Zacks Equity Research

      Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Here's Why You Should Invest in DENTSPLY (XRAY) Stock Now

      by Zacks Equity Research

      Strong prospects in emerging markets provide DENTSPLY (XRAY) a competitive edge in the MedTech space.

      AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates

      by Zacks Equity Research

      Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.

      Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition

      by Zacks Equity Research

      Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.

      AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study

      by Zacks Equity Research

      AngioDynamics' (ANGO) launches AngioDIRECT.com for enrolling participants as part of the DIRECT clinical study.

      Fluidigm (FLDM) in Focus: Stock Moves 8% Higher

      by Zacks Equity Research

      Fluidigm (FLDM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.